Tuberculin skin test conversion in rheumatologic patients during biological therapy. Recent infection or occult latent tuberculosis

Conversión de tuberculina en pacientes reumatológicos durante terapia biológica. Infección reciente o tuberculosis latente oculta

Published 2016-08-07

Open | Download
PDF (Spanish) FLIP
Issue
Vol. 26 No. 3 (2014)
Section
Editorial
How to Cite
Tuberculin skin test conversion in rheumatologic patients during biological therapy. Recent infection or occult latent tuberculosis.
rev. colomb. neumol. [Internet]. 2016 Aug. 7 [cited 2024 Nov. 21];26(3):113-5. Disponible en: https://doi.org/10.30789/rcneumologia.v26.n3.2014.36
DOI

https://doi.org/10.30789/rcneumologia.v26.n3.2014.36
Dimensions
PlumX
license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo  los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Javier Iván Lasso Apráez, MD.
Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia.
    Show authors biography

    Javier Iván Lasso Apráez, MD.,

    Internista neumólogo, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia.

     

    Article visits 261 | PDF visits 66

    Downloads

    Download data is not yet available.
    1. Raval A, Akhavan-Toyserkani G, Brinker A, Avigan M. Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med. 2007;147:699.
    2. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum. 2006;54:1075.
    3. Hsia EC, Cush JJ, Matteson EL, Beutler A, Doyle MK, Hsu B. Comprehensive tuberculosis screening program in patients with inflammatory arthritis treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials. Arthritis Care Res (Hoboken). 2013;65:309.
    4. Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNF alpha inhibitors: the utility of IFN gamma assay. Ann Rheum Dis. 2012;71:231.
    5. Keane J, Gershon S, Wise RP, Mirabile-LevensE, KasznicaJ, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098.
    6. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha California, 2002-2003. MMWR Morb Mortal Wkly Rep. 2004;53:683.
    7. Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself Rheumatol. 2007;34:706.
    8. Gomez-ReinoJJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor Inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122.
    9. Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR.
    10. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis. 2013;72 (Suppl 2).
    11. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64:625.
    12. Hatzara C, Hadziyannis E, Kandili A, Koutsianas C, Makris A, Georgiopoulos G. Frequent conversion of tuberculosis screening test during anti-tumour necrosis factor therapy in patients with rheumatic diseases. Ann Rheum Dis. 2014;0:1.
    13. Park JH, Seo GY, Lee JS, Kim TH, Yoo DH. Positive conversion of tuberculin skin test and performance of interferón reléase assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J Rheum. 2009;10:1.
    14. Cagatay T, Kilicaslan Z, Cagatay P, Mertsoylu M, Gulbaran Z, Yildiz R. TNF-alpha antagonist therapy modify the tuberculin skin test response. Rheumatol Int. 2011;9:147.
    15. American Thoracic Society. Diagnosis Standards and Classification of Tuberculosis in Adults and Children. Am J Respir Crit Care Med. 2000;161:1376.
    16. Ponce de León D, Acevedo-Vásquez E, Sánchez-Torres A, Cucho M, Alfaro J, Perich R, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis. 2005;64:1360.

    Information

    Journal history

    Keywords

    QR code

    Funding

    Support + Info: Here

     

     

    Directories and indexes

    Google Scholar profile

    Most read in the last 30 days

    Current Issue

    Sistema OJS 3.4.0.7 - Metabiblioteca |